26/03/2007 (Agence Europe) - The European Medicines Agency (EMEA) has announced in a press release that, during its 19-22 February 2007 meeting in London, it examined the adverse effects of the anti-viral drug Tamiflu, which is produced by the Roche laboratories, following new reports from Japan. These cases were detected through routine safety monitoring. The EMEA has called for the information to healthcare professionals and patients to be updated. The recommended wording for patients is...